Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Neoplasms 2Vipoma 1Uveal Melanoma 1Somatostatinoma 1Small Cell Lung Carcinoma 1Pheochromocytoma 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Gastrinoma 1Esthesioneuroblastoma, Olfactory 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

pentetreotide 1SUB1 protein, human 1Cyclophosphamide 1Cryosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Esthesioneuroblastoma, Olfactory × pentetreotide × Clear all
NCT00002947 2014-07-02

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Yale University

Phase 1 Terminated
35 enrolled
CNSDermatologicEndocrineGenitourinaryHead & NeckThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Vipoma, Glucagonoma, Head and Neck Neoplasms, Insulinoma, Adenoma, Islet Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Central Nervous System Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡